Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Hovione Scientia Limited has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners, meaning each examiner is currently reviewing exactly one action for the company. This spread of work across multiple examiners can lead to varied prosecution experiences, as each of the 3 pending office actions is reviewed by a different individual.
The 3 pending office actions are located within 2 distinct art units, suggesting some technical variety within the biotechnology field. ARNOLD, ERNST V is the busiest examiner, with 1 pending office action currently assigned. This distribution across 3 distinct examiners and 2 art units for 3 actions shows a lack of concentration in the company's current prosecution efforts. Practitioners must balance the specific technical requirements of the 2 distinct art units while responding to the individual feedback of each assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563953 | METHOD FOR SYNTHESIZING 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | FETTEROLF, BRANDON J | 14d |
| 18877710 | CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING SUGAR AND LIPID COMPOSITE PARTICLES AND PROCESS FOR MANUFACTURE | ARNOLD, ERNST V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563953 | METHOD FOR SYNTHESIZING 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | FETTEROLF, BRANDON J | 14d |
| 18877710 | CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING SUGAR AND LIPID COMPOSITE PARTICLES AND PROCESS FOR MANUFACTURE | ARNOLD, ERNST V | — |
| 18565724 | Process to Reduce Ivermectin Particle Size | SASAN, ARADHANA | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18877710 | CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING SUGAR AND LIPID COMPOSITE PARTICLES AND PROCESS FOR MANUFACTURE | ARNOLD, ERNST V | — | §103§112 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18565724 | Process to Reduce Ivermectin Particle Size | SASAN, ARADHANA | 1615 | §103 | Final Rejection | — | Pending | Nov 30, 2023 |
| 18563953 | METHOD FOR SYNTHESIZING 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | FETTEROLF, BRANDON J | 1626 | §103§112 | Final Rejection | 14d | Pending | Nov 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial